drugset / Trial / NCT00216606

The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine

NCT00216606

Phase 3 Completed 59 enrolled Janssen Pharmaceutica N.V., Belgium
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of individualized doses (50 to 200 milligrams) of topiramate tablets compared against placebo for the prevention of chronic migraine headaches over a period of 16 weeks.

Timeline

Start
2003-12
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 50 mg Oral
Subject Topiramate Small molecule 200 mg Oral

Indications